Protalix BioTherapeutics Inc
PBDA
Company Profile
Business description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Contact
2 University Plaza
Suite 100
HackensackNJ07601
USAT: +1 201 696-9345
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
213
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,290.50 | 86.60 | 1.06% |
| CAC 40 | 7,573.76 | 37.50 | 0.50% |
| DAX 40 | 22,271.67 | 29.22 | 0.13% |
| Dow JONES (US) | 40,227.59 | 114.09 | 0.28% |
| FTSE 100 | 8,417.34 | 2.09 | 0.02% |
| HKSE | 21,998.86 | 26.90 | 0.12% |
| NASDAQ | 17,366.13 | 16.81 | -0.10% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,062.47 | 36.42 | -0.30% |
| S&P 500 | 5,528.75 | 3.54 | 0.06% |
| S&P/ASX 200 | 8,075.50 | 78.40 | 0.98% |
| SSE Composite Index | 3,287.45 | 0.96 | -0.03% |